Development of hepatocellular carcinoma after sustained response to interferon therapy : how long should sustained responders with risk factors be followed?
スポンサーリンク
概要
- 論文の詳細を見る
- 2005-02-01
著者
-
Kasahara Akinori
Department Of General Medicine Osaka University Graduate School Of Medicine
-
Kasahara Akinori
Department Of Gastroenterology And Hepatology Osaka University Graduate School Of Medicine
関連論文
- Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C
- Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance
- Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B
- Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis
- Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C
- Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C
- Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection
- Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?
- The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan
- Juvenile hepatocellular carcinoma with congestive liver cirrhosis
- Interferon therapy for aged patients with chronic hepatitis C : improved survival in patients exhibiting a biochemical response
- Changes in gene expression profile by HCV core protein in cultured liver cells : analysis by DNA array assay
- Pretreatment viral load and response to interferon therapy for liver cirrhosis caused by hepatitis C virus: a multicenter controlled study
- How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients
- Development of hepatocellular carcinoma after sustained response to interferon therapy : how long should sustained responders with risk factors be followed?
- Treatment strategies for chronic hepatitis C virus infection
- Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis : a multicenter clinical study
- Hepatitis C virus 1b(II) Infection and Development of Chronic Hepatitis, Liver Cirrhosis and Hepatocellular Carcinoma : a Case-Control Study in Japan
- The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan
- Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan
- Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels : a matched case-control study
- Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients
- Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection
- Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin
- Two Cases of Acute Erythroid Leukemia Presenting with Marked Macrocytic Anemia, Reticulocytosis and Hemolysis
- Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines
- Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection